Overview

Bioavailability Study of XS003 (Nilotinib)

Status:
COMPLETED
Trial end date:
2025-01-08
Target enrollment:
Participant gender:
Summary
An open label, single-center, randomized, two-treatment, two-period, two-sequence, single dose, crossover, study under fasted and fed conditions.
Phase:
PHASE1
Details
Lead Sponsor:
Xspray Pharma AB